利伐沙班疗效怎么样？

It is a drug that can be used to treat a variety of diseases, such as the treatment of venous thrombosis in adults and the treatment of adult patients undergoing elective hip or knee replacement surgery. So what is the efficacy of rivaroxaban in treating venous thrombosis?

The efficacy of rivaroxaban in the treatment of venous thrombosis:

To explore the effect of ulinastatin combined with rivaroxaban on the coagulation function of patients after hip replacement.

A total of 102 patients who required elective hip replacement were selected and randomly divided into a treatment group and a control group, with 51 cases in each group. Control group: oral rivaroxaban combined with other conventional treatment measures; treatment group: additional intravenous infusion of ulinastatin on the basis of the treatment plan of the control group. Various coagulation indicators and clinical manifestations of the two groups of patients were tested and compared.

Results: There was no significant difference in prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-Dimer (DD), C-reactive protein (CRP) and thromboxane B2 (TXB2) between the two groups of patients before treatment ( P >0.05); PT and APTT of the patients in the treatment group 2 days after surgery and TT were significantly higher than those of the control group, and the DD and FIB of the treatment group were significantly lower than those of the control group, the difference was statistically significant ( P <0.05); within 5 days after surgery, the TXB2 (0.26±0.10) μg/L, CRP (33.81±12.48) mg/L, and total drainage volume (349.86±119.75) m of patients in the treatment group L and hospitalization time (7.26±2.85) d were respectively lower than those of the control group (0.31±0.14) μg/L, (39.42±14.79) mg/L, (417.03±134.72) ml, and (9.35±3.86) d, and the differences were significant (P<0.05).

The number of patients in the treatment group who were complicated by infection, massive bleeding from the incision, and elevated blood creatinine and blood urea during treatment was significantly lower than that in the control group; the number of patients in the treatment group (6 (11.76%)) who experienced nausea was significantly higher than 0 (0.00%) in the control group, and the differences were all statistically significant ( P <0.05).

Conclusion: Ulinastatin combined can significantly improve the hypercoagulable state of patients after hip replacement, reduce the incidence of deep vein thrombosis, and has a certain effect on promoting incision healing and immune recovery in patients.